Thus, it suggests that the elevated CD36 and DGAT2 levels contribute to VPA-induced liver steatosis, which is further supported by the improved lipid deposit and the decreased CD36/ DGAT2 levels after probiotics treatment. Here, CD36 is linked to fatty liver disease.